Trial Profile
An Open-Label Extension of Study TKT025 Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A Enzyme Replacement Therapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jun 2021
Price :
$35
*
At a glance
- Drugs Velaglucerase alfa (Primary)
- Indications Gaucher's disease type I
- Focus Adverse reactions
- Sponsors Shire
- 14 Nov 2014 New trial record